FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name ar Nash H		2. Issuer Name and Ticker or Trading Symbol Stoke Therapeutics, Inc. [STOK]									all appli Directo	ship of Reporting Pe applicable) irector fficer (give title		erson(s) to Issuer 10% Owner Other (specify						
(Last) (First) (Middle) C/O STOKE THERAPEUTICS, INC. 45 WIGGINS AVENUE						3. Date of Earliest Transaction (Month/Day/Year) 08/03/2020									COO & CBO					
(Street) BEDFORD MA 01730 (City) (State) (Zip)					4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indiv Line) X	-'					
				Non-Deri	vative	e Sec	urit	ies A	cauire	ed. D	isposed o	of. or B	enefic	ially	Owned					
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Y				ion	2A. De Execu	eeme ution	d	3. Transaction Code (Instr. 8)		4. Securities	Acquired	Acquired (A) or (D) (Instr. 3, 4 and		5. Amor Securiti Benefic Owned	unt of es ially Following	Forn (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	tion(s)			(Instr. 4)	
Common Stock 08/03/202						:0		М		5,700	A \$2.1		19	5,700			D			
Common Stock 08/03/202					020	.0			S ⁽¹⁾		5,700	D	\$24.7	4.7269 ⁽²⁾		0		D		
		T	able								sposed of , converti				wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	eemed tion Date, n/Day/Year)	4. Transa Code (8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Expira (Month	tion D		Amount Securiti Underly Derivati	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership ct (Instr. 4)	
					Code	v	(A)	(D)	Date Exerci	sable	Expiration Date	Title	Amor or Numl of Share	ber						
Employee Stock Option (Right to Buy)	\$2.19	08/03/2020			M			5,700	(3	3)	12/12/2018	Common Stock	5,70	00	\$0.00	217,311	1	D		

Explanation of Responses:

- 1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$24.35 to \$25.03 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 3. The option vests 1/48th of the shares monthly, commencing one month from the date of grant, subject to reporting person's continued service through each vesting date.

Remarks:

/s/ Stephen Tulipano, Attorney- 08/04/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.